Please login to the form below
genomes
This page shows the latest genomes news and features for those working in and with pharma, biotech and healthcare.
Gilead targets hep B in half a billion dollar deal with Precision BioSciences
Precision is pleased that initial studies with our ARCUS platform have established an important role for genome editing in their HBV program. ... The ARCUS platform is based on a natural genome-editing enzyme homing endonucleases, which identifies long
Latest news
-
Sangamo’s first gene-editing trial doesn’t convince investors
Sangamo Therapeutics has claimed a first with a trial of its genome-editing technology for rare disease Hunter syndrome, but the data didn’t convince investors and its share price closed
-
Sanofi gets EU OK for Ablynx flagship drug Cablivi
of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.
-
Human Cell Atlas gets new UK funding
compared to the Human Genome Project in its scale and ambition. ... Atlas, as a natural successor to the Human Genome Project, will be no exception.
-
Allergan builds on gene editing deal
Pushing further into the field of genome engineering, Irish pharmaceutical firm Allergan has said earlier today that it plans to develop its recently licensed CRISPR candidate to treat a retinal degenerative ... disorder. Building on its existing deal
-
Roche reshuffles its executive committee, again
Under Sabry (pictured), Genentech has seen through a number of deals, most recently signing a $1bn drug discovery alliance with Lodo Therapeutics to research genomes of microbes in soil.
More from news
Approximately 6 fully matching, plus 160 partially matching documents found.
Latest Intelligence
-
The critical role of science in healthcare communications
Entirely new fields of medicine are emerging, such as human genomics and precision therapies that are tailor-made for the individual based on specific genome sequencing.
-
Can new data aggregators shift the balance of power away from pharma?
However, it was only 20 years ago that several genomics companies, led by Human Genome Sciences Inc, thought they could secure a monopoly position over unprecedented drug targets by filing patents ... on gene sequences emerging from their own human
-
30 Women Leaders in UK Healthcare
100, 000 Genomes Project. ... It represents the world’s largest depository of whole genomes with associated clinical data, and is already being used to diagnose and personalise treatment for people with rare diseases and cancers.
-
Integrating digital biomarkers into precision medicine
In many ways, this model parallels traditional biomarker development where, for example, blood samples can be collected early in clinical research to then support genome-wide association studies to detect genetic
-
Avoiding data pitfalls in clinical research
This is a deceptively difficult task, but once patient IDs are matched within the clinical trial database, researchers have access to an analytical environment that ties together the entire genome, adverse ... With the terabytes and petabytes of data
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Editas Medicine names James Mullen as chairman
Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.
-
Editas Medicine adds to its board of directors
Editas Medicine adds to its board of directors. Jessica Hopfield will also serve on the genome editing firm's audit committee. ... Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who
-
Former GSK CEO joins Synthego’s advisory board
I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”. ... Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”.
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
-
Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel
Genome editing group Intellia Therapeutics has appointed Moncef Slaoui and Frank Verwiel to join its board of directors at a time when the board is establishing a Science and Technology Committee, ... We look forward to their guidance as we continue to
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Genetic counsellors: the new healthcare influencers?
Genetic counsellors: the new healthcare influencers? Blue Latitude Health explores the relationship between physicians and genetic counsellors, and the impact this has on turning precision medicine into a reality for oncology patients. In April 2018,
-
Mastering the precision medicine opportunity
Craig Venter, the internationally renowned scientist behind the Human Genome Project and head of Human Longevity Inc goes so far to say that data will fundamentally transform the way medicine is
-
Medical information in precision medicine
As the cost of sequencing continues to drop, it will become feasible to sequence the entire human genome easily.
-
Big data, privacy and the rise of genomic testing
The cost of sequencing the entire human genome has dropped from $100M in 2001 to less than $1000 in 2014. ... The golden age of data. Experts predict up to 50 million genomes will be sequenced by 2022.
-
Marketing strategy in complex environments
genome. With personalised medicine, products with defined patient populations are becoming increasingly prevalent and are transforming certain therapy areas into finely segmented markets.
More from PMHub
Approximately 2 fully matching, plus 12 partially matching documents found.
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Systematic Review Lead- London
-
Negotiable
- Account Director or Senior Account Director
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Healthcare PR Senior Account Manager
-
Salary TBC
-
Account Manager
-
Negotiable
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Senior Medical Writer
-
Salary is DOE
Subscribe to our email news alerts
- Moving annual total (MAT)
- AZ prepares to file COPD triple, taking on rival GSK
- J&J files ‘breakthrough’ bladder cancer drug in US
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Teva wins FDA OK for crucial migraine drug
- NHS wins legal fight with pharma over off-label Avastin
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Just::Health Communications
Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
